If you've tried to research the clinical evidence for craniosacral therapy, you've probably found a confusing picture. Some reviews report positive findings. Others conclude there are no significant effects. Studies from similar time periods reach different conclusions. That's not unusual in a young field with a small number of trials, but it does make it hard to know what to make of what you're reading.
This article gives an honest summary of what the major systematic reviews and meta-analyses have found, where they agree and where they don't, and what the overall state of the evidence really means. The aim isn't to argue for or against CST. It's to help you read the research landscape clearly.
The short version: a small number of trials, a lot of methodological variation across them, and reviews that reach different conclusions partly because of which studies they include and how they handle the variation.
The 2019 Jäkel and von Hauenschild review
One of the more widely cited positive reviews is the 2019 meta-analysis by Jäkel and von Hauenschild, which looked at 10 randomised controlled trials in chronic pain populations. It found statistically significant short-term effects on both pain and functional outcomes.
That's a genuinely positive finding, and it's worth knowing about. The usual caveats apply: individual trial quality varied, sample sizes were generally small, and the confidence intervals were wide. The result points to a signal worth investigating further, not a settled verdict.
The chronic-pain focus matters too. The meta-analysis wasn't asking about CST across all conditions. It was specifically looking at pain outcomes. Condition-specific analyses tend to be more informative than all-condition pooled ones, which makes this one of the stronger pieces of review-level evidence on the positive side.
The 2023 headache-specific review
A 2023 systematic review and meta-analysis looked specifically at CST for headache. It found a statistically significant reduction in headache pain intensity, which sounds good. But the reviewers described the effect as a 'clinically unimportant change' and rated the certainty of the evidence as very low.
What that means: the average effect across the included trials was statistically detectable but small enough that researchers judged it unlikely to translate into a meaningful change in daily life for most people. 'Very low certainty' means they had significant concerns about the reliability of the underlying studies.
This is one of those findings where the headline can mislead in either direction. The statistically significant result is real. So is the low certainty and small average effect. For individuals, a clinically unimportant average doesn't mean nobody experiences meaningful relief. Averages smooth over individual variation.
The 2024 Ceballos-Laita and Amendolara reviews
Two 2024 reviews widened the evidence base under analysis and reached negative overall conclusions. The Ceballos-Laita review included 15 RCTs across a wide range of conditions and found no significant benefits for any of them. The Amendolara review analysed 24 RCTs covering 1,613 participants — the largest meta-analysis of CST so far — and also found no statistically significant effects.
These are substantive findings and can't be waved off. The Amendolara review especially, with its larger sample, carries real statistical weight. The conclusion that no significant effects were found across conditions is a genuine negative signal for CST as a broad-spectrum therapy.
That said, both reviews pooled results across heterogeneous conditions, which means condition-specific effects — where they exist — can be diluted into non-significance by averaging across conditions where evidence is weak or absent. That's a methodological reality of broad-condition meta-analyses, not a reason to dismiss the findings.
What to make of the conflict
Taken together, the review-level evidence on CST is mixed and generally low-certainty. The positive findings are real but small and uncertain. The negative findings are consistent but partly explained by study heterogeneity and condition pooling.
This doesn't mean CST is worthless, and it doesn't mean the research proves it works. It means the field is still in a relatively early stage of evidence-gathering, with a small number of methodologically varied trials and reviews doing their best to make sense of that variation.
If you're considering CST for a specific condition, the most useful thing is to look at the trial-level evidence for that condition rather than just the broad-condition reviews. Some conditions — certain pain presentations, infant colic, specific headache types — have more focused trial evidence than others. The broader reviews tell part of the story, not all of it.
The evidence base for CST is small, variable in quality, and still developing. That honest picture doesn't resolve the question of whether CST is right for you, but it gives you a more accurate foundation for the decision than either pure enthusiasm or pure scepticism.